

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
AZRIA, MOISE ET AL.
APPLICATION NO: 10/565455
FILED: APRIL 5, 2006
FOR: USE OF CALCITONIN IN OSTEOARTHRITIS

ART UNIT: 1646
EXAMINER: XIE, XIAOZHEN

MS: Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

supplemental to the Information Disclosure Statement filed May 7, 2007.


If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134 in the name of Novartis.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of the references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



Leslie Fischer
Attorney for Applicant
Reg. No. 58,393

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-9308

Date: 7/17/09